AIM ImmunoTech disclosed interim data from its Phase 2 DURIPANC study, which combines the TLR‑3 agonist Ampligen (rintatolimod) with AstraZeneca’s checkpoint inhibitor Imfinzi (durvalumab) in patients with metastatic pancreatic cancer who progressed after FOLFIRINOX.
The investigator‑initiated, open‑label trial was conducted at Erasmus Medical Center in the Netherlands and enrolled 18 patients. Interim analysis shows promising signals: 64 % of evaluable patients achieved overall survival greater than six months, and 3 of 14 evaluable patients had progression‑free survival exceeding six months, with an additional 3 remaining progression‑free at the data cutoff. No grade ≥ 2 immune‑related or systemic toxicities were reported, and no dose‑limiting toxicities were observed.
Safety data were favorable, and patients reported meaningful improvements in quality of life as measured by validated patient‑reported outcome instruments. The safety profile aligns with expectations from earlier Ampligen studies and supports continued combination development.
The 19.7‑month median overall survival figure cited in the original article originates from a prior 57‑subject early‑access program of Ampligen monotherapy, which compared favorably to the 8.6‑month survival of standard care. The DURIPANC interim data do not yet provide a median OS or PFS; the study remains ongoing and the reported signals are preliminary.
These interim results reinforce AIM’s strategy to pursue a pancreatic cancer indication and may accelerate the path to a Phase 3 trial. The data also strengthen the company’s position when seeking regulatory approvals or partnership opportunities, potentially enhancing investor confidence in the Ampligen‑durvalumab combination.
Investors reacted positively, citing the promising interim data, favorable safety profile, and quality‑of‑life improvements as key drivers of the market response.
AIM plans to expand the DURIPANC cohort and, contingent on continued encouraging signals, will move toward a Phase 3 study while pursuing regulatory approvals and potential collaborations to bring the combination to patients in need.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.